Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.69 USD | +16.45% | -1.47% | -1.47% |
10:43am | SANOFI : UBS maintains a Buy rating | ZD |
Jul. 08 | Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours | MT |
Sales 2024 * | 46.33B 50.12B | Sales 2025 * | 49.75B 53.83B | Capitalization | 115B 125B |
---|---|---|---|---|---|
Net income 2024 * | 7.04B 7.61B | Net income 2025 * | 8.57B 9.27B | EV / Sales 2024 * | 2.64 x |
Net Debt 2024 * | 6.95B 7.52B | Net Debt 2025 * | 2.51B 2.72B | EV / Sales 2025 * | 2.36 x |
P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
13.5
x | Employees | - |
Yield 2024 * |
4.2% | Yield 2025 * |
4.42% | Free-Float | 87.13% |
Latest transcript on Sanofi SA
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Lise Kingo
BRD | Director/Board Member | 62 | 20-04-27 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
1st Jan change | Capi. | |
---|---|---|
+57.48% | 827B | |
+39.11% | 634B | |
-7.18% | 350B | |
+15.37% | 319B | |
+7.45% | 294B | |
+13.64% | 240B | |
+15.33% | 221B | |
+0.45% | 219B | |
+8.14% | 167B |